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selective or non-selective and weak opioids (codeine, tramadol, dextropropoxyphene) 
was extracted and analysed. RESULTS: A total of 23 456 prescriptions were analysed, 
18 187 prescribed to adults [18–64 years] and 5 269 to elderly ≥65 years of age 
[65–101 years]. The proportion of NSAID prescriptions for non-selective plus selective 
Cox-2-inhibitors (Coxibs), did not change during the 5- year period, 91.1, 91.3, 91.4, 
92 and 91.5 % of patients were prescribed an NSAID. The proportion of prescriptions 
for traditional non-selective NSAIDs increased from 83.9% to 90.3 % from year 2004 
to 2008 among adult patients and from 69.7% to 78.7% among elderly. The propor-
tion of prescriptions for Coxibs decreased between 2004 and 2008 and were pre-
scribed to 3.6 % of patients in this study in 2008. Co-prescription of gastric protective 
therapy was made in 12–20 % of prescriptions with no differences between NSAID, 
Coxibs and non-NSAID. CONCLUSIONS: In this review of NSAID prescription 
utilization among patients with a diagnosis of musculoskeletal pain shows an extensive 
use of anti-inﬂammatory agents without co-prescription of gastro-protective medica-
tion. The impact of this high utilization of NSAIDs without co-prescription of gastro-
protective agents on the risk for upper gastro-intestinal complications warrants further 
evaluation.
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OBJECTIVES: Acute chest syndrome (ACS) is the leading cause of death and the 
second most common cause of hospitalization in patients with sickle cell disease 
(SCD), yet it is unclear whether hospital experience (i.e., volume) is associated with 
improved clinical and resource-use outcomes. In this study, we compared inpatient 
mortality, length of stay (LOS) and total costs between high- and low-SCD volume 
hospitals treating ACS patients. METHODS: Using the 2006–2007 Nationwide Inpa-
tient Sample (NIS), we identiﬁed ACS patients based on ICD-9-CM codes 517.3 (ACS) 
or 486 (pneumonia) among discharges with SCD (Clinical Classiﬁcation Code 61). 
SCD volume represented the average number of SCD discharges from a hospital per 
year over the 2-year study period. Given that majority of patients were treated in a 
relatively small number of hospitals, the top decile was selected to represent high 
volume hospitals. We used generalized estimating equations to evaluate whether 
hospital-level SCD experience was independently associated with inpatient mortality 
(binomial distribution, logit link), LOS (negative binomial distribution, log link) and 
costs (gamma distribution, log link) between volume groups while controlling for 
gender, age, payer, number of comorbidities, and hospital characteristics, including 
rural vs. urban location, teaching status, bed size, ownership type, and hospital region. 
RESULTS: Among 6,857 ACS discharges across 688 hospitals, 4154 and 2703 were 
treated in high- and low-volume hospitals, respectively. Median age was 22 in high-
volume hospitals and 29 in low-volume hospitals. In unadjusted analyses, inpatient 
mortality (0.9% vs. 1.7%, p = 0.004), mean LOS (6.9 vs. 7.4, p = 0.005), and mean 
costs ($11,358 vs. $12,013, p = 0.077) were lower in high vs. low volume hospitals. 
After adjustment for patient and hospital characteristics, hospital volume was no 
longer signiﬁcantly associated with inpatient outcomes. CONCLUSIONS: Hospital 
volume was not signiﬁcantly associated with inpatient mortality, LOS, and total costs 
among ACS patients.
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OBJECTIVES: To assess induction and maintenance infusion patterns of inﬂiximab 
(IFX) treatment in ulcerative colitis (UC) patients receiving 1, 2, or 3 induction doses. 
METHODS: A retrospective analysis of medical claims from an administrative data-
base was conducted for UC patients newly starting IFX. Patients were required to 
have age ≥18 yrs, 2 diagnosis codes for UC, IFX index date between September 1, 
2005 and January 31, 2008, and ≥ 26 months of continuous enrollment (minimum 
12 months before and 14 months after the index date). Patients with select pre-index 
inﬂammatory disorders were excluded. The analysis evaluated induction (IFX doses 
during ﬁrst 56 days post-index) and maintenance (doses >56 days and <12 months 
post-induction). Persistence during maintenance was deﬁned by a medication posses-
sion ratio (MPR) of >80%. Results were stratiﬁed by the number of induction doses 
(1, 2, or 3). RESULTS: A total of 354 UC patients were included in the analyses: 
mean (SD) age of 44 (14) yrs; 48.3% female; 62.4% received IFX in the outpatient 
ofﬁce setting. There were 27, 83, and 244 patients in the 1, 2, and 3 induction dose 
groups, respectively. The overall mean (SD) number of days during the induction 
period was 35 (14), and days increased with the number of induction doses. During 
the maintenance period, patients received an overall mean (median) of 5 (6) infusions. 
The cohort receiving 3 induction infusions had the highest percentage of patients with 
an MPR > 80%. Infusion patterns for the ﬁrst year post-induction were consistent 
with recommended prescribing information, with a median of 56 days between infu-
sions. CONCLUSIONS: The majority of IFX patients received 3 induction doses. 
Induction and maintenance infusion patterns were consistent with prescribing recom-
mendations, especially for those patients receiving 3 induction doses. These data 
support administering 3 IFX doses during induction to ensure appropriate dosing and 
optimal medication adherence during maintenance.
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OBJECTIVES: U.S. Food and Drug Administration (FDA)-approved prescribing infor-
mation recommends inﬂiximab (IFX) administration at 0, 2, 6 and every 8 weeks with 
potential dose escalation based on patient response in Crohn’s Disease (CD) patients. 
Minimal real world dosing data are available in this population. This study describes 
IFX dosing patterns in patients with CD treated in an outpatient hospital setting. 
METHODS: A retrospective longitudinal analysis using the Premier PerspectiveTM 
Database, a U.S.-based hospital database, was conducted. Inclusion criteria were an 
outpatient hospital discharge CD diagnosis between July 1, 2000 and March 31, 2008, 
IFX-naïve (received no IFX in the prior 180 days), and ≥ 3 IFX doses within ≤56 days 
of the index infusion. Exclusion criteria included patients with other selected inﬂam-
matory diseases. Treatment duration was deﬁned as the time between the index and 
last IFX dose. Hospital outpatient dosing schedules were analyzed for the 4th through 
15th IFX dose, representing the ﬁrst two years of IFX maintenance treatment. 
RESULTS: A total of 1439 IFX-treated patients with CD were identiﬁed. Mean (SD) 
age was 42.8 (15.4) years; 59% were female. Mean (SD) treatment duration was 415 
(425) days. Patients received a mean (SD) of 8.4 (7.5) IFX administrations. Mean (SD) 
index IFX dose was 429 (152) mg. During the initial two years of maintenance IFX 
administration, the highest observed mean IFX dose represented a 10% increase 
during the maintenance period and a 13% increase compared to the index IFX dose. 
Median time between administrations was 56 days for all maintenance infusions. 
CONCLUSIONS: The mean IFX dose remained between 439 and up to 483 mg 
throughout the maintenance treatment. Administration schedule was consistent with 
FDA-approved prescribing information. These data suggest that IFX dosing patterns 
in CD patients remain relatively stable with minimal dose escalation occurring when 
administered in real world outpatient hospital settings.
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OBJECTIVES: To present the design of a lifetime Markov model that compares the 
cost-effectiveness of primary prophylaxis versus on-demand treatment with recombi-
nant factor VIII among children with severe hemophilia A. METHODS: Prophylactic 
infusions of rFVIII-FS have been shown to reduce the frequency of bleeding episodes 
and the risk of joint damage in children with hemophilia A with no pre-existing joint 
damage. Clinical studies have shown signiﬁcant improvement in outcomes with the 
use of prophylactic treatment, as well as apparent gains in health-related quality of 
life. However, recombinant clotting factors are also associated with relatively high 
cost. Using a lifetime Markov model, the cost-effectiveness of primary prophylaxis 
treatment was compared to on-demand treatment. This model is among the few that 
model long-term cost and effectiveness and is unique in that it takes into account the 
probability of inhibitor development, use of central venous access device (CVAD), and 
total bleeding risk including CNS and joint bleeds. Prophylactic treatment is assumed 
to be from birth until 16 years of age. Built in the model were also 5 health states: 
being alive, surgery, inhibitor development, disability and deceased. SUMMARY: 
From this model, cost-effectiveness estimations can be made for patients receiving 
on-demand treatment versus primary prophylaxis. Cost-effectiveness can vary by the 
frequencies of events between treatment arms, age where prophylaxis begins and ends, 
dose/frequency of factor VIII, cost of medications and key hospital-related events, and 
the probability of achieving speciﬁed clinical endpoints. CONCLUSIONS: The 
strengths and distinguishing characteristics of this model versus previously published 
hemophilia prophylaxis models include: long-term cost and effectiveness, probability 
of inhibitor development, use of CVAD, and CNS bleeds. There are a few study limita-
tions related to the lack of data for model assumptions. Obtaining stronger evidence 
for these parameters may substantiate or potentially improve the model results.
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BACKGROUND: Decision modeling is commonly used to assess the cost-utility of 
drugs or technologies. For a real-world application, models should include aspects of 
the disease relevant to the patient. In recent years, patient focus groups have been used 
to help deﬁne health utility values. METHODS: Hemophilia patients attending the 
National Hemophilia Foundation’s 61st Annual Meeting were invited to participate 
in a focus group to inform the development of a decision model, evaluating prophy-
